Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database

Background and purpose: Testosterone is an essential sex hormone in maintaining masculine characteristics, which is prescribed for male hypogonadism as testosterone replacement treatment (TRT). Herein, we investigated long-standing controversies about the association between TRT and major adverse ca...

Full description

Bibliographic Details
Main Authors:	Hui Zhao, Jun-Min Li, Zi-Ran Li, Qian Zhang, Ming-Kang Zhong, Ming-Ming Yan, Xiao-Yan Qiu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-07-01
Series:	Frontiers in Pharmacology
Subjects:	pharmacovigilance testosterone treatment TT major adverse cardiovascular events MACE FAERS
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1182113/full

Similar Items

Examining the safety of mirabegron: an analysis of real-world pharmacovigilance data from the US FDA adverse event reporting system (FAERS) database
by: Junwei Wang, et al.
Published: (2024-03-01)

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database
by: Zhao Li, et al.
Published: (2024-03-01)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
by: Zhiwei Cui, et al.
Published: (2023-10-01)

Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS
by: Shu Tang, et al.
Published: (2022-10-01)

Risk factors for drug-related acute pancreatitis: an analysis of the FDA adverse event reporting system (FAERS)
by: Lin Zhang, et al.
Published: (2023-11-01)

Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database
by: Fan Zou, et al.
Published: (2024-02-01)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022-11-01)

Alpelisib-related adverse events: The FDA Adverse Event Reporting System Database (FAERS) pharmacovigilance study
by: Yun Li, et al.
Published: (2024-03-01)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2023-05-01)

Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database
by: Wensheng Liu, et al.
Published: (2023-11-01)

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for alpelisib
by: Yu Lin, et al.
Published: (2024-03-01)

Sodium-glucose co-transporter-2 inhibitor (SGLT2i) treatment and risk of osteomyelitis: A pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023-02-01)

Safety of SGLT2 Inhibitors: A Pharmacovigilance Study from 2013 to 2021 Based on FAERS
by: Xiang Zhou, et al.
Published: (2021-12-01)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
by: Yan Wu, et al.
Published: (2023-08-01)

Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study
by: Tengfei Yuan, et al.
Published: (2023-11-01)

Pharmacovigilance Analysis of Serious Adverse Events Reported for Biologic Response Modifiers Used as Prophylaxis against Transplant Rejection: a Real-World Postmarketing Experience from the US FDA Adverse Event Reporting System (FAERS)
by: A. K. Ali
Published: (2013-04-01)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
by: Yamin Shu, et al.
Published: (2022-10-01)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023-12-01)

Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
by: SHE Youjun, GUO Zihan, ZHANG Zhongwei, DU Qiong
Published: (2023-10-01)

Post-marketing safety of immunomodulatory drugs in multiple myeloma: A pharmacovigilance investigation based on the FDA adverse event reporting system
by: Tingting Jiang, et al.
Published: (2022-12-01)

Fluoroquinolone-associated suspected tendonitis and tendon rupture: A pharmacovigilance analysis from 2016 to 2021 based on the FAERS database
by: Yamin Shu, et al.
Published: (2022-09-01)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseResearch in context
by: Chaozheng Zhou, et al.
Published: (2023-05-01)

Signal mining and risk analysis of Alprazolam adverse events based on the FAERS database
by: Feng Huang, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of Rucaparib: Post-marketing Pharmacovigilance Data
by: Qilin Zhang, et al.
Published: (2023-08-01)

Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database
by: Yi Zheng, et al.
Published: (2023-01-01)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
by: Jeanne M. Schilder, et al.
Published: (2023-08-01)

Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system
by: Rui Xiong, et al.
Published: (2023-09-01)

Post-Marketing Safety Concerns With Secukinumab: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Yamin Shu, et al.
Published: (2022-06-01)

A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)
by: Linlin Tang, et al.
Published: (2024-02-01)

A real-world disproportionality analysis of Everolimus: data mining of the public version of FDA adverse event reporting system
by: Bin Zhao, et al.
Published: (2024-03-01)

A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system
by: Mingdi Liu, et al.
Published: (2024-01-01)

Detection of potential safety signals related to the use of remdesivir and tocilizumab in the COVID era during pregnancy, resorting to open data from the FDA adverse event reporting system (FAERS)
by: Beatriz Marinho Silva Romão, et al.
Published: (2024-01-01)

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
by: Jianxing Zhou, et al.
Published: (2022-12-01)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022-11-01)

Safety assessment of cenobamate: real-world adverse event analysis from the FAERS database
by: Shihao Chen, et al.
Published: (2024-03-01)

Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database
by: Ying Jiang, et al.
Published: (2024-04-01)

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
by: Jingrui Zou, et al.
Published: (2022-11-01)

Ocular adverse events associated with anti-VEGF therapy: A pharmacovigilance study of the FDA adverse event reporting system (FAERS)
by: Pan Ma, et al.
Published: (2022-11-01)